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Introduction
Healthy cell function in peripheral tissues is characterized by 
the ability of metabolism to adapt to changes in nutrient avail-
ability and oxidize multiple energy substrates (Muoio, 2014; 
Stanley et al., 2014; Olson et al., 2016). For example, skeletal 
muscle will readily switch from robust use of fatty acids during 
fasting to substantial glucose oxidation upon feeding. This met-
abolic flexibility is a characteristic of healthy skeletal muscle, 
and an impaired ability to shift between oxidation of fatty acids 
and glucose in response to nutrient availability and hormonal 
status is associated with obesity, insulin resistance, and reduced 
aerobic fitness (Kelley, 2005; Muoio, 2014). A loss of meta-
bolic plasticity is associated with disease pathogenesis in not 
only type 2 diabetes, but also cardiac disease (Fillmore and Lo-
paschuk, 2013) and even certain cancers, where the metabolic 
changes associated with tumorigenesis can include a hardwired 
reliance on specific metabolic pathways (Tennant et al., 2010; 
Pavlova and Thompson, 2016).
Unlike peripheral tissues, however, it is generally accepted 
that the brain lacks considerable metabolic flexibility. Glucose 
is its obligatory substrate (Clarke and Sokoloff, 1994; Bélanger 
et al., 2011; McKenna et al., 2012), and the brain is thought to 
rarely oxidize nonglucose substrates apart from ketone bodies 
during starvation (Cunnane et al., 2011). Despite a substantial 
energy demand, the brain has a limited capacity to store glyco-
gen or use gluconeogenesis to compensate for changes in glu-
cose provision, so changes in blood glucose supply can have 
profound effects on brain function if the arterial concentration 
drops appreciably (Clarke and Sokoloff, 1994; Cryer, 2007).
Multiple forms of neurodegenerative disease are asso-
ciated with energetic and metabolic deficits (Johri and Beal, 
2012), and links between insufficient metabolic plasticity and 
neurodegeneration are emerging as well. For example, hypome-
tabolism of glucose can manifest long before clinical symptoms 
in Alzheimer’s disease (Cunnane et al., 2011), and epidemiolog-
ical data consistently link insulin resistance with an increased 
risk of cognitive impairment (Cunnane et al., 2011; Craft, 2012; 
de la Monte, 2012). Links between metabolic inflexibility and 
disease etiology are further underscored by evidence that oxida-
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tion of nonglucose substrates may be beneficial in certain forms 
of neurodegeneration. For example, mouse models that reduce 
the capacity of neurons and astrocytes to oxidize glucose but 
promote ketone body oxidation exhibit resistance to epileptic 
seizures (Giménez-Cassina et al., 2012). This aligns with the 
longstanding observation that low-carbohydrate diets can con-
fer dramatic benefits to some forms of medically refractory sei-
zure disorders (Hartman et al., 2007). In fact, this promise has 
triggered the clinical evaluation of ketogenic diets for several 
forms of acute and chronic neurodegenerative disease, although 
a mechanistic understanding of the potential benefits remains 
unresolved (Masino and Rho, 2012; Lutas and Yellen, 2013).
An overlap between oxidation of specific metabolic 
substrates and neuronal physiology could exist at handling of 
amino acids, which are indispensable for neurotransmission 
but can also be used as metabolic substrates (Yudkoff et al., 
2008; McKenna et al., 2012). In the mammalian central nervous 
system, glutamate is the dominant excitatory neurotransmitter 
(balanced with inhibitory γ-aminobutyric acid [GABA]) and is 
responsible for the synaptic plasticity associated with learning 
and memory (Meldrum, 2000). During glutamatergic neuro-
transmission, packaged glutamate in a presynaptic neuron is 
released to the synapse, where it binds to ionotropic and me-
tabotropic receptors on postsynaptic neurons to trigger activity. 
It is then rapidly cleared by high-affinity transporters, allow-
ing a continuous cycle of neurotransmitter activity (Maragakis 
and Rothstein, 2001). Maintaining homeostatic levels of syn-
aptic glutamate comes at a tremendous energetic cost (Nich-
olls, 2009), and predictably, periods of metabolic stress result 
in dysregulated glutamate handling (Choi and Rothman, 1990). 
When glutamate rises to toxic levels, excessive receptor stim-
ulation triggers intracellular Ca2+ overload that subsequently 
causes mitochondrial complex I dysfunction (Kushnareva et al., 
2005) and activates neurotoxic signaling cascades (Szydlowska 
and Tymianski, 2010). Glutamate excitotoxicity not only is a 
hallmark of acute neuropathologies, such as epilepsy, stroke, 
and traumatic brain injury, but is also thought to contribute to 
progressive neurodegenerative diseases including Alzheimer’s 
disease (Coyle and Puttfarcken, 1993).
In many peripheral tissues, metabolism of glutamate (and 
glutamine) is essential for energetics, biosynthesis, redox ho-
meostasis, and hormonal control of metabolism (DeBerardinis 
and Cheng, 2010). However, this stands in stark contrast to the 
conventional central nervous system model, in which gluta-
mate metabolism is widely considered to be compartmentalized 
within the glutamine-glutamate cycle because of its central role 
in neurotransmission (Daikhin and Yudkoff, 2000; McKenna et 
al., 2012; Schousboe et al., 2013). In the canonical model, as-
trocytes supply glutamine to neurons, where it is deamidated to 
glutamate, packaged into vesicles, released to the extracellular 
space to activate glutamate receptors, and sequestered by as-
trocytes for resynthesis of glutamine. It is sometimes acknowl-
edged that glutamate metabolism is closely associated with 
TCA cycle function, although the focus is often on astrocytic 
metabolism (Daikhin and Yudkoff, 2000; Yudkoff et al., 2008; 
McKenna et al., 2012; Schousboe et al., 2013). As such, the 
concept of whether alterations in TCA cycle metabolism can 
adjust neuronal glutamate handling, vesicular release, and exci-
totoxic injury remains largely unconsidered.
To reconcile the potential benefits from oxidation of non-
glucose substrates with the perceived, inexorable dependence of 
neuronal metabolism on glucose, we mapped the pattern of cel-
lular metabolism in response to reduced mitochondrial pyruvate 
carrier (MPC) activity. The MPC is an inner-membrane trans-
porter that facilitates pyruvate uptake from the cytoplasm into 
mitochondria (Bricker et al., 2012; Herzig et al., 2012). It is a 
central regulator of mitochondrial substrate utilization (Vacanti 
et al., 2014), and restrictions in mitochondrial pyruvate uptake 
can potentiate the use of fatty acids and a range of amino acids 
to fuel cellular energetics and biosynthesis (Vacanti et al., 2014; 
Yang et al., 2014; Gray et al., 2015; McCommis et al., 2015).
Broadly, mapping the pattern of neuronal metabolism 
upon MPC inhibition allowed us to (a) determine the extent 
of metabolic flexibility in neurons and (b) determine whether 
adjustments in neuronal substrate oxidation could affect sus-
ceptibility to injury. We report that neuronal metabolism is 
characterized by metabolic plasticity, and oxidative metabolism 
can be maintained in spite of large reductions in mitochondrial 
pyruvate uptake because of a selective increase in glutamate 
oxidation. As such, and perhaps counterintuitively, reductions 
in mitochondrial pyruvate metabolism can be neuroprotective: 
increased glutamate oxidation decreases the glutamate available 
for synaptic release and, in turn, minimizes the positive feed-
back cascade of excitotoxic injury.
Results
Cortical neurons remain viable in culture 
after inhibition of MPC activity
Before exploring neuronal metabolic flexibility, it was first nec-
essary to determine whether primary cortical neurons remain 
viable in response to restricted mitochondrial pyruvate uptake. 
This was assessed by treatment with the specific MPC inhibitor 
UK5099 (Hildyard et al., 2005; Fig. 1, a and b). Surprisingly, 
neurons maintained in standard culture conditions remained vi-
able over 72 h of treatment (Fig. 1 c). UK5099 reduced the max-
imal capacity of neurons to oxidize pyruvate by >50% (Fig. 1 d) 
but, unlike the respiratory complex III inhibitor antimycin A, did 
not cause cell death. This difference demonstrates that blocking 
mitochondrial pyruvate uptake elicits a different metabolic re-
sponse than respiratory chain inhibition. Moreover, it suggests 
that neurons have a significant, inherent capacity to oxidize 
nonglucose substrates (stored endogenously or provided in cul-
ture medium) to meet their energetic and metabolic demands.
Neurons readily oxidize nonglucose 
substrates
Having demonstrated that viability was unchanged upon re-
duced mitochondrial pyruvate uptake, we then characterized the 
capacity of neurons to drive cellular energetics with alternative 
substrates. Initially, we chose to focus on ketone bodies, as the 
brain is known to oxidize these during starvation, and branched 
chain amino acids (BCAAs), as significant BCAA oxidation is 
observed in some terminally differentiated cells (Vacanti et al., 
2014; Green et al., 2016). Respirometry in permeabilized cells 
demonstrated that neuronal mitochondria can oxidize not only 
canonical mitochondrial substrates (pyruvate/malate, succinate/
rotenone, glutamate/malate) and ketone bodies (β-hydroxybu-
tyrate), but also the branched chain keto-acid catabolites of leu-
cine, isoleucine, and valine (Figs. 2 a and S1 a).
To measure alternative substrate oxidation in the con-
text of intact neurons, we conducted bioenergetic experiments 
in customized medium modeled after culture conditions but 
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lacking respiratory substrates, allowing substrate provision to 
be experimentally controlled (Table 1). We estimated the ATP 
production rate from oxidative phosphorylation and glycolysis 
by applying known stoichiometries to rates of respiration and 
lactate efflux and used UK5099 to acutely restrict mitochon-
drial pyruvate uptake and potentiate use of other substrates. 
Predictably, neurons offered only glucose and pyruvate in this 
medium increased their glycolytic rate but could not meet their 
overall ATP demand in response to 90-min UK5099 treatment. 
The altered rates of glycolysis and total ATP production, how-
ever, were entirely reversed when this simplified medium was 
supplemented with β-hydroxybutyrate and leucine (Fig. 2 b). In 
fact, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
(FCCP)–stimulated respiration indicated that cortical neurons 
have a remarkable capacity to fuel respiration using these al-
ternative energy substrates that far exceeds what is required to 
meet the basal cellular energy requirements (Fig. 2 c and Fig. 
S1, b and c). These experiments reveal that neurons have a sub-
stantial capacity to oxidize nonglucose substrates, but provide 
little information about whether, and to what extent, these sub-
strates are used in rich cell culture medium.
We therefore used stable isotope tracers ([13C6]glucose, 
[13C4]β-hydroxybutyrate, or [13C6]leucine) and mass spectrom-
etry to further characterize neuronal oxidation of alternative 
substrates under basal conditions. These experiments were 
conducted in rich medium replete with a broad complement of 
amino acids and oxidizable substrates (Neuro-c; see Materials 
and methods and Table 1). Incorporation of isotopically labeled 
carbon into TCA intermediates can provide quantitative infor-
mation about the relative flux of each substrate into the TCA 
cycle (Fig. S1 d). Additionally, as acetyl CoA serves as the pre-
cursor for de novo lipogenesis, labeling of total palmitate can be 
reliably used to quantify isotope incorporation into the lipogenic 
acetyl CoA pool with isotopomer spectral analysis (Fig. S1 e).
We found that nonglucose substrates contributed signifi-
cantly to the lipogenic acetyl CoA pool (Fig. 2 d) and enriched 
TCA cycle intermediates (Fig. 2, e and f; and Fig. S1, f and g). 
Leucine-derived carbon enriched TCA cycle intermediates and, 
surprisingly, accounted for nearly half as much lipogenic acetyl 
CoA as glucose (Fig. 2 d). The relative incorporation of leucine 
into fatty acids and citrate was comparable to that of differenti-
ated adipocytes (Green et al., 2016) and human skeletal muscle 
myotubes (Vacanti et al., 2014), suggesting that leucine may be 
a more significant oxidative and biosynthetic carbon source in 
neurons than is generally appreciated (Kajimoto et al., 2014). 
Further demonstration of neuronal metabolic plasticity was 
apparent when culture medium was supplemented with 2 mM 
β-hydroxybutyrate. Mitochondrial glucose utilization signifi-
cantly decreased as previously observed (Lund et al., 2009), and 
the contribution of β-hydroxybutyrate to de novo lipogenesis 
and enrichment of TCA cycle intermediates was greater than or 
equal to those of glucose (Fig. 2, e and f; and Fig. S1, f and g). 
The combination of respirometry and stable isotope tracing re-
veals that neurons have an intrinsic capacity to drive energetics 
Figure 1. Neuronal viability is maintained 
despite MPC inhibition. (a) The MPC (blue) 
sits at a central hub of cellular energetics, 
facilitating transport of cytoplasmic pyruvate 
into the mitochondrial (mito.) matrix. GLUT, 
glucose transporter; MCT, monocarboxylate 
transporter; ETC, electron transport chain. 
(b–d) All data are n = 4; presented as mean ± 
SEM. **, P < 0.01. (b) Uncoupler-stimulated 
respiration in permeabilized cortical neurons 
and astrocytes in response to 5 µM UK5099 
demonstrates specific inhibition of facilitated 
pyruvate transport. Treatment was made 
acutely in assay medium lacking albumin. 
P/M, 5 mM pyruvate with 1 mM malate and 
2 mM dichloroacetate; G/M, 5 mM glutamate 
with 5  mM malate; S/R, 10  mM succinate 
with 2 µM rotenone; and MePyr/M, 25 mM 
methyl pyruvate with 5 mM pyruvate, 1 mM 
malate, and 2  mM dichloroacetate. (c) Vi-
ability of rat cortical neuronal cultures in re-
sponse to UK5099 or 1 µM antimycin A (anti. 
A) treatment (tx.). (d) Efficacy of UK5099 is 
demonstrated in neurons by measuring FCCP- 
stimulated, pyruvate-driven respiration in per-
meabilized cells after 24-h drug treatment.
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and biosynthesis with alternative mitochondrial substrates, and 
do so at substantial rates under basal conditions.
Bioenergetics are maintained upon MPC 
inhibition despite a negligible increase in 
β-hydroxybutyrate and leucine oxidation
Establishing that neurons are metabolically flexible allowed us 
to subsequently characterize the metabolic adaptations to reduc-
tions in mitochondrial pyruvate uptake, with the ultimate goal 
of studying whether enforcing oxidation of nonglucose sub-
strates could be beneficial to neurons. After treating neurons in 
rich culture medium with UK5099 for 24 h to increase their reli-
ance on alternative mitochondrial substrates, we quantified iso-
tope enrichment into TCA cycle intermediates. Upon treatment, 
incorporation of glucose-derived carbon into the TCA cycle 
was significantly reduced (Figs. 3 a and S2 a), as expected. A 
profound reduction in mitochondrial pyruvate uptake, however, 
did not compromise global mitochondrial bioenergetics. Basal 
respiration rates were entirely maintained (Fig. 3 b) without a 
significant change in intracellular lactate levels (Fig. 3 c), indi-
cating no substantial change in the balance between oxidative 
phosphorylation and glycolysis. Additionally, rates of de novo 
palmitate synthesis were not significantly changed upon chem-
ical MPC inhibition (Fig. S2 b). Collectively, these results sug-
gest that mitochondrial oxidation of nonglucose substrates was 
increased to maintain the metabolic requirements of the cell.
Given the substantial capacity of neurons to oxidize β-hy-
droxybutyrate and leucine (Fig. 2), we first hypothesized that 
oxidation of these substrates was increased to compensate for 
decreased mitochondrial pyruvate uptake. Unexpectedly, how-
ever, there was little to no increase in the oxidation of these 
substrates upon UK5099 treatment. Incorporation of carbon 
derived from β-hydroxybutyrate or leucine into TCA cycle in-
termediates was largely unchanged (Fig. 3, d and e), and their 
contribution to the lipogenic acetyl CoA pool was only mar-
ginally increased despite a two-thirds reduction in lipogenesis 
from glucose-derived carbon (Fig. 3 f). These data indicate that 
neurons adapt to MPC inhibition in rich medium by increasing 
oxidation of a previously unconsidered substrate.
Glutamate oxidation is specifically 
increased upon MPC inhibition  
to maintain anaplerosis
To better understand the metabolic adaptation of neurons to 
MPC inhibition, we measured abundances of TCA cycle in-
termediates and amino acids. We observed significant changes 
Figure 2. Metabolic flexibility in primary cortical neurons. (a) ADP-stimulated respiration in permeabilized neurons shows that neuronal mitochondria 
can oxidize a variety of substrates (n = 3). S/R, 10 mM succinate with 2 µM rotenone; G/M, 5 mM glutamate with 5 mM malate; P/M, 5 mM pyruvate 
with 1 mM malate and 2 mM dichloroacetate; β-HB/M, 5 mM β-hydroxybutyrate with 1 mM malate; KIC/M, 5 mM α-ketoisocaproate with 1 mM malate; 
KMV/M, 5 mM α-keto-β-methylvalerate with 1 mM malate; KIV/M, 5 mM α-ketoisovalerate with 1 mM malate; and M, 1 mM malate. (b) UK5099 does not 
compromise rates of ATP production in intact neurons when β-hydroxybutyrate and leucine are added to medium containing glucose and pyruvate. Total 
ATP production rates are estimated as the sum of ATP produced from oxidative phosphorylation (Ox. Phos.) and glycolysis (Glyco.); [glucose], 10 mM; 
[pyruvate], 1 mM; [β-hydroxybutyrate], 3 mM; [leucine], 2 mM; [UK5099], 0.1 µM for 90 min. (c) Maximal, FCCP-stimulated respiration is maintained 
despite MPC inhibition when medium is supplemented with β-hydroxybutyrate and leucine (concentrations as in b). n = 5. (d–f) The extent to which glucose, 
β-hydroxybutyrate, and leucine are metabolized under control, unchallenged conditions was determined with stable isotope tracing in rich culture medium 
over 24 h. Nc, Neuro-c rich medium; Nc + β-HB, Neuro-c with 2 mM β-hydroxybutyrate. [leucine], 0.8 mM. (d) β-Hydroxybutyrate and leucine contribute 
significantly to the lipogenic acetyl CoA as determined by isotopomer spectral analysis (ISA). (e and f) MPE of labeled carbon into citrate (e) and malate 
(f) also shows incorporation of β-hydroxybutyrate and leucine into TCA cycle pools. Conditions as in d. Unless stated otherwise, all data are n = 4 and 
presented as mean ± SEM. *, P < 0.05; **, P < 0.01.
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in the intracellular abundance of glutamate and aspartate, as 
UK5099 treatment dropped total glutamate levels by ∼50%, 
with a concomitant, twofold increase in aspartate (Figs. 4 a and 
S2 c). Notably, overall abundances of other amino acids and 
TCA cycle intermediates were not significantly changed (Fig. 
S2 d), apart from decreases in citrate and alanine (because of 
reduced mitochondrial pyruvate uptake [Vacanti et al., 2014]) 
as well as proline (a direct metabolite of glutamate). This pat-
tern of metabolic reprogramming is consistent with that ob-
served upon MPC inhibition in immortalized and primary cells 
including myocytes, cancer cells, and the retina, and suggests 
increased oxidation of glutamate via aspartate aminotransferase 
(Bricker et al., 2012; Du et al., 2013; Vacanti et al., 2014; Yang 
et al., 2014; Gray et al., 2015).
In the context of other cell types, the result would per-
haps be unsurprising: glutamine is appreciated as an important 
energetic and biosynthetic substrate, particularly in cancerous 
or highly proliferative cells (DeBerardinis and Cheng, 2010). 
In neuronal physiology, however, it is widely perceived that 
glutamate metabolism in the brain is compartmentalized as a 
neurotransmitter (Daikhin and Yudkoff, 2000; McKenna et al., 
2012; Schousboe et al., 2013). The data in Fig. 4 a, however, 
suggest that the abundance of the neuronal glutamate pool can 
be readily adjusted by TCA cycle metabolism. Moreover, iso-
tope enrichment of glutamate and aspartate mirrored the com-
position of TCA cycle intermediates during studies of neuronal 
metabolic plasticity described earlier (Fig. S2, e and f, relative 
to Fig. 2, e and f; and Fig. S1, f and g). This suggests that gluta-
mate is synthesized de novo from glucose and other TCA cycle 
substrates and is consistent with recent in vivo metabolic trac-
ing from human and rodent brains (Marin-Valencia et al., 2012; 
Tardito et al., 2015). Collectively, the data demonstrate that 
both the abundance and the molecular composition of the neu-
ronal glutamate pool can be adjusted by TCA cycle metabolism.
We subsequently tested the hypothesis that glutamate 
oxidation is specifically up-regulated in response to reduced 
pyruvate oxidation. Neurons cannot be offered exogenous glu-
tamate as a respiratory substrate, most notably because it will 
cause excitotoxic cell death from excessive N-methyl-d-aspar-
tate (NMDA) receptor agonism. However, in addition to its 
synthesis from α-ketoglutarate via transamination, glutamate is 
derived at significant rates from glutamine via deamidation. We 
therefore conducted a series of experiments in which stabilized 
l-alanyl-l-glutamine (GlutaMAX) in neuronal culture me-
dium was replaced with [13C5]glutamine to track incorporation 
of glutamine-derived carbon (Fig. S3 a). The NMDA receptor 
antagonist MK801 was included to prevent excitotoxic injury 
from glutamate generated by spontaneous deamidation of gluta-
mine. Over 24 h, UK5099 treatment profoundly increased glu-
tamine uptake (Fig. 4 b), flux of glutamine-derived acetyl CoA 
to newly synthesized palmitate (Fig. 4 c), and enrichment from 
glutamine-derived carbon into TCA cycle intermediates (Figs. 
4 d and S3 b). Consistent with this observation, cortical neurons 
can also use glutamine to fuel respiration in response to MPC 
inhibition (Fig. S3 c).
Metabolic alterations in the cytoplasm were further indic-
ative of enhanced glutamate oxidation. Global respiratory inhi-
bition and a shift from oxidative phosphorylation to glycolysis 
generally results in an oxidized cytoplasm (increased NAD+/
NADH ratio) caused by a decreased pyruvate/lactate ratio. Upon 
neuronal MPC inhibition, however, the pyruvate/lactate ratio in-
creased (Fig. 3 c), and glucose-derived carbon was incorporated 
to a greater extent into pyruvate and serine relative to lactate 
(Fig. 4 e). This suggests a more reduced cytoplasm (Fig. S3 d), 
perhaps helping to drive glutamate oxidation by making the ma-
late-aspartate shuttle more energetically favorable (Fig. S3 e).
Naturally, a question arises as to why glutamate oxida-
tion is preferentially increased in neurons upon MPC inhibition, 
rather than a broad increase in the oxidation of multiple other 
substrates observed in other systems (Vacanti et al., 2014; Gray 
et al., 2015). We speculated that this might be to compensate 
Table 1. Neuro-c medium composition
Item Concentration
mM
Amino acids
 Glycine 0.40
 l-Alanine 0.02
 l-Arginine 0.40
 l-Asparagine 0.01
 l-Cysteine 0.26
 l-Histidine 0.20
 l-Isoleucine 0.80a
 l-Leucine 0.8–2.0a
 l-Lysine 0.80
 l-Methionine 0.20
 l-Phenylalanine 0.40
 l-Proline 0.07
 l-Serine 0.40
 l-Threonine 0.80
 l-Tryptophan 0.08
 l-Tyrosine 0.40
 l-Valine 0.80a
Vitamins
 Choline chloride 0.029
 d-Calcium pantothenate 0.008
 Folic acid 0.009
 Niacinamide 0.033
 Pyridoxal hydrochloride 0.02
 Riboflavin 0.001
 Thiamine hydrochloride 0.012
 Vitamin B12 5.02 × 10−6
 i-Inositol 0.04
Inorganic salts
 Calcium chloride 1.801
 Ferric nitrate 2.48 × 10−4
 Magnesium chloride 0.814
 Potassium chloride 5.333
 Sodium chloride 51.724
 Sodium phosphate (monobasic) 0.906
 Zinc sulfate 6.74 × 10−4
Additives
 Sodium bicarbonate 26.19 mMa
 Hepes 5-10.9 mMa
 Phenol red 0.02 mM
 B27 supplements 2% (vol/vol)a
 GlutaMAX 2 mMa
 Penicillin 100 U/mla
 Streptomycin 100 µg/mla
 l-Glutamine 0.5–2.0 mMa
 Glucose 8–10 mMa
 Pyruvate 0.22–1.0 mMa
 β-Hydroxybutyrate 2–3 mMa
aAdded as indicated further in the text.
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for reductions in glucose anaplerosis (Chinopoulos, 2013). In 
addition to generating acetyl CoA via pyruvate dehydrogenase 
(PDH), pyruvate can be converted to the TCA cycle interme-
diates oxaloacetate or malate via the CO2-fixing reactions of 
pyruvate carboxylase or malic enzyme (Fig. 4 f; Hassel, 2001; 
Chinopoulos, 2013). These anaplerotic reactions add net carbon 
to the TCA cycle, replenishing pools of intermediates that are 
siphoned off for biosynthesis. Conversely, PDH, or any reaction 
that provides carbon to the TCA cycle via acetyl CoA, does not 
contribute net carbon to the TCA cycle (Figs. 4 f and S1 d). If 
UK5099 restricted a major source of anaplerosis, the compen-
satory response could not simply be to increase oxidation of 
substrates that generate acetyl CoA (such as β-hydroxybutyrate 
and leucine), but would instead require a substrate that also 
adds net carbon to the TCA cycle (i.e., glutamate).
Significant differences in the citrate mass isotopomer 
distributions from glucose and β-hydroxybutyrate provided 
initial hints of significant neuronal glucose anaplerosis under 
basal conditions (Fig. S3 f). To definitively test this, we offered 
neurons a [3-13C1]glucose tracer, which contains an isotopic 
label on the third glucose carbon. This label is lost when py-
ruvate is oxidized via PDH but is retained on TCA cycle in-
termediates if pyruvate is metabolized via anaplerotic reactions 
(Fig. 4 f). We observed substantial labeling from this tracer in 
citrate, malate, and aspartate (via oxaloacetate transamination). 
Labeling was significantly decreased by UK5099 (Fig.  4  g) 
and directly attributable to anaplerotic reactions rather than 
PDH (Fig. S3 g). As such, decreased glucose anaplerosis upon 
MPC inhibition provides a rationale for a preferential increase 
in glutamate oxidation.
Organotypic hippocampal cultures 
show reciprocal oxidation of pyruvate 
and glutamate
Next, we tested whether the metabolic profile observed upon 
MPC inhibition in pure neuronal cultures could extend to a 
more complex and representative model of brain tissue func-
tion. For this, we used organotypic hippocampal slice cultures, 
which retain many aspects of the cellular heterogeneity and syn-
aptic architecture of the tissue (Gähwiler et al., 1997). Although 
neuron-specific oxidation of glutamate cannot be discerned 
given the multicellular nature of slice cultures, this system can 
nonetheless be used to broadly test whether the metabolic pro-
file of MPC inhibition persists in a more intact model system. 
We treated hippocampal slice cultures with 10 µM UK5099 for 
48 h in the presence of isotopic tracers. This elicited a small 
but significant decrease in citrate enrichment from uniformly 
labeled glucose (Fig. 5 a), indicating a modest reduction in mi-
tochondrial pyruvate uptake. Indeed, the resulting metabolic 
profile in slice cultures reproduced the hallmarks seen in disso-
ciated neuronal cultures: (a) enrichment from glucose-derived 
carbon preferentially into pyruvate and serine rather than lac-
Figure 3. Neuronal MPC inhibition does not compromise bioenergetics despite little/no increase in ketone body or leucine oxidation. (a) MPE of [U-13C6]
glucose indicates that UK5099 treatment restricts incorporation of glucose carbon into TCA cycle intermediates. (b) Basal mitochondrial respiration is not 
compromised after 24-h UK5099 treatment. n = 3. (c) MPC inhibition increases the intracellular abundance of pyruvate without a significant change in 
lactate. (d and e) Treatment with UK5099 does not cause generalized increases in MPE from [U-13C4]β-hydroxybutyrate (d) or leucine (e) into TCA cycle 
intermediates. (f) Relative contribution from [U-13C6]glucose to lipogenic acetyl CoA is substantially decreased upon reduced pyruvate uptake, with slight 
increases from [U-13C4]β-hydroxybutyrate and [U-13C6]leucine. All experiments were conducted in Neuro-c as in Fig. 2 (d–f) and detailed in Materials and 
methods. Data are n = 4 unless otherwise noted and presented as mean ± SEM. In a and c–f: [UK5099], 10 µM for 24 h. β-HB, β-hydroxybutyrate; Cit., 
citrate; Fum., fumarate; Gluc., glucose; Lac., lactate; Leuc., leucine; Mal., malate; Pyr., pyruvate; Succ., succinate. *, P < 0.05; n.s., not significant.
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tate (Fig. 5 b), (b) increased ratios of aspartate/glutamate and 
pyruvate/lactate (Fig.  5  c), and (c) a slight but significant in-
crease in enrichment from glutamine-derived carbon into citrate 
(Fig. 5 d). This reciprocal regulation of pyruvate and glutamate 
oxidation is consistent with earlier results and supports the con-
cept that pyruvate metabolism by the TCA cycle can regulate 
glutamate handling in intact, multicellular neural systems.
MPC inhibition protects from 
excitotoxic cell death by lowering evoked 
glutamate release
Under conditions of metabolic stress that excessively depolar-
ize neurons, synaptic glutamate rises to excitotoxic levels that 
exacerbate neuronal injury. Therefore, having shown that block-
ing mitochondrial pyruvate uptake lowers the intraneuronal glu-
tamate pool, we tested whether it also reduces the glutamate 
pool released upon plasma membrane depolarization. Indeed, 
neurons treated with UK5099 released less glutamate to the 
extracellular medium upon depolarization from treatment with 
veratridine (which prevents Na+-channel closure) plus ouabain 
(which inhibits Na+/K+-ATPase; Fig. 6 a). Additionally, stable 
isotope tracing with uniformly labeled [13C6]glucose or [13C5]
glutamine tracers revealed an altered composition of the re-
leased glutamate upon MPC inhibition, suggesting a shift away 
from mitochondrial glucose oxidation and toward that of gluta-
mine/glutamate (Fig. 6 b). These data provide initial evidence 
that the glutamate pool oxidized during MPC inhibition is asso-
ciated with the pool released upon depolarization.
Figure 4. Glutamate oxidation is selectively up-reg-
ulated upon MPC inhibition to maintain anaplerosis in 
cortical neurons. (a) Relative intracellular abundance 
of glutamate (Glu) decreases and aspartate (Asp) 
increases. (b) Uptake of glutamine, a precursor of 
glutamate, increases from the extracellular medium. 
(c) Relative contribution of [U-13C5]glutamine to the 
lipogenic acetyl CoA pool is enhanced. (d) MPE of 
[U-13C5]glutamine incorporated into TCA cycle inter-
mediates increases. (e) Enrichment from [U-13C6]glu-
cose demonstrates greater proportional increases in 
fully labeled pyruvate and serine compared with lac-
tate. (f) Schematic depicting use of a [3-13C1]glucose 
tracer to demonstrate glucose anaplerosis. The la-
beled carbon is lost via the PDH reaction but retained 
by the anaplerotic reactions of pyruvate carboxylase 
(PC) and malic enzyme (ME). The two-carbon interme-
diate acetyl CoA does not add net carbon to the TCA 
cycle because CO2 is lost in both the isocitrate dehy-
drogenase (IDH) and α-ketoglutarate dehydrogenase 
(α-KGDH) reactions. (g) UK5099 treatment lowers 
the percentage of single-labeled carbon from [3-13C1]
glucose on malate, citrate, and aspartate, indicating 
significant flux from glucose through anaplerotic re-
actions. All experiments were conducted in Neuro-c 
medium as detailed in Materials and methods, with 
comparisons made between control conditions and 
10 µM UK5099 treatment for 24 h. Data are n = 4 
unless otherwise stated and are presented as mean ± 
SEM. Asp, aspartate; Glu, glutamate; Pyr., pyruvate; 
Ser., serine. *, P < 0.05; **, P < 0.01.
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Because the data indicated that potentiating oxidation 
of glutamate can limit the size of the released pool, we hy-
pothesized that MPC inhibition may protect from excitotoxic 
injury. Indeed, cortical neurons treated with UK5099 were pro-
tected from excitotoxic cell death in neuronal culture medium 
(Fig. 6 c). The protection afforded by pyruvate carrier inhibition 
was not additive to the protective effects of MK801, reinforcing 
that the mechanism of protection by MPC inhibition was medi-
ated by the NMDA receptor. A similar profile of protection by 
UK5099 and MK801 was observed in assays conducted iden-
tically but lacking exogenously added glutamate (i.e., death in-
duced only from the stress associated with fluid change during 
the assay; Fig. S4 a). This suggests that some excitotoxic death 
can be attributable to endogenous glutamate release and points 
to a spatio-temporal component within the neuronal popula-
tion that contributes to the observed excitotoxicity. Although 
MK801 provided only ∼50% protection from excitotoxic death 
(Fig. 6 c), it is essential to note that conducting experiments in 
rich medium replete with several oxidizable substrates provides 
substantial protection over traditional assays in simple salts–
based medium (Fig. S4 b). In fact, an ancillary finding of these 
experiments is that supplementing conventional, simple salts–
based medium with nonglucose substrates provides protection 
during excitotoxicity (Fig. S4, c and d; Haces et al., 2008; Net-
zahualcoyotzi and Tapia, 2014).
The primary result that UK5099 protects from excitotoxic 
cell death informs a mechanism for the protective effects of py-
ruvate carrier inhibition: oxidation of the neuronal glutamate 
pool decreases the glutamate released to the extracellular space 
upon de-energization and limits the excitotoxic, positive feed-
back cascade. To test this concept and explicitly reveal a role for 
NMDA receptor–mediated depolarization, neurons were treated 
with 100 µM NMDA for a brief duration that evoked glutamate 
release but did not acutely compromise viability (Fig. S4, e and 
f). As expected, neurons treated with UK5099 released less glu-
tamate to the extracellular space upon NMDA treatment, and 
this again was not additive to the effects of MK801 (Fig. 6 d).
Finally, to directly link MPC inhibition to reductions in the 
vesicular glutamate pool in presynaptic terminals, we conducted 
whole-cell patch-clamp recordings. The presynaptic, readily re-
leasable glutamate pool was measured by recording postsyn-
aptic currents while applying hypertonic sucrose-containing 
solution (500 mM for 4 s) to primary mouse cortical pyramidal 
neurons. Neurons treated with UK5099 exhibited a significantly 
Figure 5. Organotypic hippocampal slice cultures reproduce hallmarks 
of MPC inhibition. (a) MPE of citrate from [U-13C6]glucose is decreased. 
(b) Increases in enrichment from a [U-13C6]glucose tracer are observed in 
fully labeled pyruvate and serine, but not lactate. Color scheme as in panel 
a. (c) Ratios of aspartate/glutamate and pyruvate/lactate in slice cultures 
are elevated. Metabolite ratios are internally normalized parameters and 
independent of the amount of starting material. (d) MPE of citrate from [U-
13C5]glutamine is increased. All experiments were conducted in MEM as 
detailed in Materials and methods, with comparisons made between con-
trol conditions and 10 µM UK5099 treatment for 48 h. Data are n = 6 and 
presented as mean ± SEM. Asp., aspartate; Glu., glutamate; Lac., lactate; 
Pyr., pyruvate; Ser., serine. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 6. UK5099 protects cortical neurons from excitotoxic injury by 
lowering the releasable glutamate pool. (a) The relative amount of glu-
tamate released upon depolarization from 25 µM veratridine with 1 µM 
ouabain is lowered upon MPC inhibition. (b) MPE from [U-13C5]glutamine 
(Gln.) and [U-13C6]glucose (Gluc.) into glutamate demonstrates that MPC 
inhibition can affect the composition of the glutamate pool released by 
veratridine/ouabain: enrichment from glucose decreases, whereas enrich-
ment from glutamine increases after UK5099 treatment. Cells were treated 
with stable isotope tracers in Neuro-c lacking β-hydroxybutyrate. (c) MPC 
inhibition is protective from excitotoxic cell death in Neuro-c, measured 
24  h after glutamate exposure. Protective effects from UK5099 are not 
additive to the protection afforded by the NMDA receptor antagonist 
MK801. (d) The quantity of glutamate released to the extracellular medium 
after 90-min treatment with 100 µM NMDA is reduced by UK5099. All 
data are n = 4 unless otherwise stated and presented as mean ± SEM. 
[UK5099], 10 µM for 24 h; MK801, 10 µM. *, P < 0.05; **, P < 0.01.
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smaller peak current density in excitatory postsynaptic currents 
in response to sucrose shock (Fig. 7, a and b). Importantly, MPC 
inhibition did not significantly change either neuronal mem-
brane capacitance (Fig. 7 c), reflecting unaltered cell membrane 
area, or synaptic density as measured by colocalization of post-
synaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptors with presynaptic vesicular glutamate transporter 
1 (vGlut1; Fig. 7, d and e; and Fig. S5). The electrophysiologi-
cal data reinforce a model in which potentiating neuronal gluta-
mate oxidation by MPC inhibition can attenuate the glutamate 
pool released upon depolarization (Fig. 8).
Discussion
Here we present evidence that TCA cycle metabolism and 
glutamatergic neurotransmission are linked via mitochondrial 
pyruvate uptake. The inarguable dependence of brain energy 
metabolism on arterial glucose is, of course, not mutually ex-
clusive with neurons mobilizing glutamate as an oxidizable 
substrate. Glutamate is demonstrably de novo synthesized from 
glucose-derived carbon, and based on cellular context and met-
abolic demands, stored glutamate could be appropriated for 
either neurotransmission or oxidative metabolism. Of course, 
the data cannot exclude increased flux of other anaplerotic re-
actions to help compensate for MPC inhibition, most notably 
propionyl CoA production from valine or isoleucine. However, 
based on other cell types with comparable rates of BCAA oxida-
tion (Green et al., 2016), such changes would likely be marginal 
relative to the substantive increase seen in glutamate oxidation.
A distinction should be drawn between the require-
ments for robust MPC activity during gestation and develop-
ment as opposed to maturity. Homozygous knockout of either 
MPC paralog is embryonically lethal in mice (McCommis et 
al., 2015; Vanderperre et al., 2016), likely because of neuro-
developmental deficits (Vanderperre et al., 2016). After matu-
rity, however, slight reductions in MPC activity could allow 
energy demands to be met while adjusting neurotransmitter 
balance. Indeed, a developmental requirement for a metabolic 
enzyme does not preclude its pharmacologic inhibition as a vi-
able therapeutic strategy.
The context in which MPC inhibition would be benefi-
cial is essential to its putative therapeutic value. In the healthy 
brain, substantial MPC inhibition could compromise cognitive 
Figure 7. Patch-clamp electrophysiology demon-
strates that MPC inhibition reduces evoked glutamate 
release. (a) Representative traces of EPSCs in response 
to hypertonic sucrose shock indicate decreased release 
of presynaptic glutamate. (b) Peak current density is 
lowered after 5  µM UK5099 treatment for 24  h.  (c) 
Membrane capacitance after 5 µM UK5099 treatment 
for 24 h is unchanged. (d and e) Size (d) and density 
(e) of GluA2 puncta colocalized with vGlut1 are un-
changed by UK5099 treatment. All data are n ≥ 16 
from three independent preparations and are presented 
as mean ± SEM. **, P < 0.01, by unpaired t test.
Figure 8. The data support a model whereby 
pyruvate carrier inhibition increases gluta-
mate oxidation to maintain energetics and 
anaplerosis. This decreases the quantity of glu-
tamate available for evoked release and can 
protect from excitotoxic cell death. GLN., glu-
tamine; GLU., glutamate; MIM, mitochondrial 
inner membrane.
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function, indicated by the fact that arterial glucose can drop 
to only ∼40% of normal levels before loss of consciousness 
(Cryer, 2007). Under pathological conditions such as ischemia, 
however, synaptic glutamate can increase by orders of magni-
tude within minutes (Rossi et al., 2000). Tonic levels of MPC 
inhibition may therefore protect from the excitotoxic sequelae 
of stroke by attenuating the synaptic glutamate concentration. 
Many efforts targeting excitatory amino acid receptors (e.g., po-
tent NMDA receptor antagonists) have stalled because of pro-
hibitory neurological side effects, exposing a need to explore 
alternative approaches to treat excitotoxicity (Lipton, 2004). 
Lowering synaptic glutamate by promoting its oxidation may 
provide a more forgiving approach that allows continued recep-
tor function. In fact, weaker NMDA receptor antagonists such 
as memantine have far better clinical profiles than potent inhib-
itors such as MK801 (Lipton, 2004). Targeting mitochondrial 
pyruvate uptake to limit excitotoxic injury will likely involve 
the discovery of a novel class of MPC inhibitors, as current 
compounds are either nonspecific (Divakaruni et al., 2013; Du 
et al., 2013) or reactive nucleophiles such as UK5099 that are 
unattractive drug candidates (Hildyard et al., 2005). To that end, 
a thiazolidinedione that inhibits the MPC but exhibits reduced 
affinity toward peroxisome proliferator–activated receptor-γ has 
recently shown efficacy in several animal models of Parkinson’s 
disease (Ghosh et al., 2016). Because endogenous regulators of 
mitochondrial pyruvate uptake have yet to be defined, the extent 
to which physiological regulation of MPC activity affects glu-
tamatergic neurotransmission is currently unclear.
Speculatively, these results may also provide insight into 
the mechanism of how ketogenic diets can exert beneficial neu-
rological effects, particularly with regard to medically refractory 
seizure disorders. Oxidation of ketone bodies cannot entirely 
compensate for reductions in brain glucose metabolism because 
they are not anaplerotic, so it is possible that neurotransmitter 
balance is adjusted in response to low-carbohydrate diets be-
cause of increased glutamate oxidation. Amino acid handling 
has been proposed as a means by which these diets are anticon-
vulsant (Yudkoff et al., 2008), although that study proposed a 
different mechanism whereby the presence of ketones increases 
flux of glutamate to GABA to control excitability via increased 
inhibitory signaling. Nonetheless, in vivo inhibition of seizures 
by a broad class of ionotropic glutamate receptor antagonists 
establishes a role for glutamate receptor overactivity in seizure 
disorders (Chapman, 2000). The metabolic pattern revealed 
here provides a strong foundation for in vivo testing of MPC 
inhibition to treat excitotoxic injury and, perhaps, suggests that 
the MPC may be a candidate target for a long-desired class of 
anticonvulsants that seek to pharmacologically mimic the bene-
fits of the ketogenic diet (Masino and Rho, 2012).
Materials and methods
Animals and cell/tissue culture
All animal protocols were approved by the Institutional Animal Care 
and Use Committee of the University of California, San Diego. Cortical 
neurons were generated from embryonic day 18 Sprague-Dawley rats 
as described previously (Kushnareva et al., 2005). Cultures were ∼95% 
pure as determined by immunocytochemical staining to antineuronal 
nuclei or 200 kD antineurofilament. Cells were plated onto poly-d-ly-
sine–coated wells of black-walled 96-well plates, Seahorse XF96 
plates, or six-well dishes and maintained at 37°C in a humidified incu-
bator with 5% CO2. Cells for 96-well plate-based assays were seeded at 
2.5 × 104 cells/well and maintained in maintenance medium composed 
of 200 µl Neurobasal (Thermo Fisher Scientific) medium supplemented 
with 1× B27 serum-free supplement (Thermo Fisher Scientific), 2 mM 
GlutaMAX (Thermo Fisher Scientific), 100 U/ml penicillin, and 100 
µg/ml streptomycin. Cells in six-well dishes were seeded at 1.75 × 
105 cells/well and maintained in 4 ml medium. Half the medium was 
replaced every 3–4 d. Experiments in 96-well plates were conducted 
at day in vitro (DIV) 13–17, and six-well dishes were used at 19–21 
DIV. For electrophysiology, cortical cultures from FVB/N mice were 
prepared as previously described (except glutamine was replaced with 
GlutaMAX [Buren et al., 2016]), plated at 650 cells/mm2, and used at 
DIV 17–18. Cortical astrocytes were prepared according to established 
methods (Kim and Magrané, 2011).
Organotypic hippocampal slice cultures were prepared as 
previously described (Stoppini et al., 1991) from postnatal day 6 
Sprague-Dawley rats. After animals were anesthetized with isoflurane 
inhalation, cerebral hemispheres were quickly dissected in medium 
containing 218  mM sucrose, 4  mM KCl, 1.3  mM NaH2PO4, 5  mM 
MgCl2, 1 mM CaCl2, 26 mM NaHCO3, 10 mM glucose, and 30 mM 
Hepes, pH 7.4. 300-µm hippocampal slices were generated using an 
automated tissue chopper (McIlwain) and transferred to slice culture 
medium composed of MEM (50-019; Corning) supplemented with 
20% horse serum, 12.9 mM glucose, 1 mM glutamine, 2 mM MgCl2, 
1  mM CaCl2, 0.07  mM ascorbic acid, 5.2  mM NaHCO3, 30.5  mM 
Hepes, and 1 µg/ml insulin. Three slices were plated per cell culture 
insert (PICM03050; EMD Millipore) and fed with 0.75 ml culture me-
dium. Medium was replaced every 2 d, and isotope tracers were added 
12–14 d after preparation.
Viability
Viability was determined by measuring release of lactate dehydroge-
nase (LDH) in the extracellular medium after a given treatment (Cy-
totoxicity Detection kit #11-644-793-001; Roche; used according to 
manufacturer’s instructions). Cell death was defined as the percentage 
of LDH activity associated with the assay medium relative to cell- 
associated activity. LDH activity was assessed with kinetic measure-
ments over 5 min, and cell-associated LDH activity was determined 
by collecting medium after 30-min treatment with 2% (wt/vol) Triton 
X-100 to fully lyse cells.
Medium formulation
Custom Neuro-c (Table 1) used for studies with dissociated neuronal 
cultures was modeled after Neurobasal medium (Thermo Fisher Sci-
entific) and purchased from ScienCell Research Laboratories. Neuro-c 
was composed with a base medium, to which additives were selectively 
included (Table 1) to a given experiment as indicated later.
Respirometry
Oxygen consumption measurements were made using a Seahorse XF96 
or XFe96 Analyzer with a minimum of four biological replicates for each 
experiment and a minimum of five technical replicates per plate. Only 
the inner 60 wells of the 96-well plate were used for measurements; the 
outer rim was filled with 200 µl PBS before plating to minimize effects 
of temperature and evaporation during long-term incubation.
Permeabilized cells. Neurons were permeabilized with 3 nM re-
combinant, mutant perfringolysin O (PFO; XF PMP; Agilent Technolo-
gies; Divakaruni et al., 2013), offered specific substrates, and respiration 
was measured as previously described (Divakaruni et al., 2014b). Phos-
phorylating (state 3) respiration was measured in the presence of 4 mM 
ADP, and maximal respiration was measured after addition of 2 µM 
oligomycin and sequential additions of 2 µM FCCP. Rates were cor-
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rected for background/nonmitochondrial respiration with addition of 
1 µM rotenone and 1 µM antimycin A. Substrate concentrations are as 
follows: 5 mM pyruvate with 1 mM malate and 2 mM dichloroacetate 
(P/M); 5 mM glutamate with 5 mM malate (G/M); 10 mM succinate 
with 2 µM rotenone (S/R); 5 mM β-hydroxybutyrate with 1 mM ma-
late (β-HB/M); 5 mM α-ketoisocaproate with 1 mM malate (KIC/M); 
5 mM α-keto-β-methylvalerate with 1 mM malate (KMV/M); 5 mM 
α-ketoisovalerate with 1 mM malate (KIV/M); 1 mM malate (M); and 
5 mM pyruvate with 1 mM malate, 2 mM dichloroacetate, and 25 mM 
methyl pyruvate (MePyr/M).
Intact cells. To measure the ability of respiration to acutely adapt 
to MPC inhibition (Fig. 2, b and c; and Fig. S2, b and c), maintenance 
medium was exchanged with Neuro-c (Table  1) supplemented with 
5 mM Hepes, 8 mM glucose, and 1 mM pyruvate. Where indicated, 
medium was also supplemented with 3  mM β-hydroxybutyrate or 
3  mM β-hydroxybutyrate plus 2  mM leucine. Cells were pretreated 
with UK5099 (3–300 nM) for 1  h.  Respiration was measured under 
basal conditions as well as after injection of 2  µM oligomycin, two 
sequential additions of 250 nM FCCP, and 0.2 µM rotenone with 1 µM 
antimycin A.
When measuring the bioenergetic consequences of long-term 
UK5099 treatment (Fig. 3 b), it was necessary to conduct respirometry 
measurements under conditions closely matching those used for stable 
isotope tracing. Therefore, after treatment with UK5099 for 24 h, mea-
surements were made with a Seahorse XFe Analyzer placed in a Coy 
Hypoxia Chamber (Coy Laboratory Products) with O2 set to 21.7% (am-
bient) and CO2 set to 5% to reproduce the environment of a cell culture 
incubator (Grassian et al., 2014). Maintenance medium was replaced 
with Neuro-c (Table 1) supplemented with 26.19 mM sodium bicarbon-
ate, 2% (vol/vol) B27 supplement, 10.9 mM Hepes, 2 mM GlutaMAX, 
0.8  mM leucine, 0.8  mM isoleucine, 0.8  mM valine, 8  mM glucose, 
2 mM β-hydroxybutyrate, 0.22 mM pyruvate, and 0.02 mM phenol red. 
Rates were corrected for background/nonmitochondrial respiration with 
addition of 1 µM rotenone and 1 µM antimycin A.
Lactate efflux
Under conditions matching respirometry experiments for acute 
UK5099 treatment (Fig. 2 b), the extracellular medium was harvested, 
and lactate was quantified using an enzymatic assay as previously de-
scribed (Mookerjee et al., 2015). In brief, sample medium was mixed 
1:1 with a solution of 1 M Tris, pH 9.8, 20 mM EDTA, 400 mM hydra-
zine (309400; Sigma-Aldrich), 40 U/ml LDH (L3916; Sigma-Aldrich), 
and 4 mM NAD+. The reaction velocity was measured after 2 min (340 
nm excitation/460 emission), and values were calibrated against known 
lactate standards (L7022; Sigma-Aldrich).
ATP production rates
The ATP production rate was estimated as the sum of ATP produced 
from oxidative phosphorylation and glycolysis. The mitochondrial ATP 
production rate was estimated by multiplying the oligomycin-sensitive 
respiration rate by 5.45 (a P/O ratio of 2.73 [Brand, 2005; Watt et al., 
2010], multiplied by 2 to convert rates from pmol O2/min to pmol 
O/min). Because the rate of oligomycin-sensitive respiration will 
slightly overestimate the rate of proton leak-driven respiration (thereby 
underestimating the rate of ATP-linked respiration), a correction was 
made assuming a 10% overestimate of the proton leak rate (Affourtit 
and Brand, 2009). Glycolytic ATP production rates were calculated as-
suming a 1:1 stoichiometry between lactate efflux and ATP production 
(Divakaruni et al., 2014a). This will underestimate the actual rate, as it 
does not account for the glycolytic ATP produced during the formation 
of pyruvate that is ultimately diverted away from LDH and oxidized by 
mitochondria (Mookerjee et al., 2015).
Protein quantification
Cells were lysed with RIPA (50  mM Tris, pH 7.4, 150  mM NaCl, 
1% [wt/vol] NP-40, 0.5% [wt/vol] sodium deoxycholate, and 0.1% 
[wt/vol] sodium dodecyl sulfate), and protein quantification was 
made using the bicinchoninic assay method (BCA protein assay kit; 
Thermo Fisher Scientific).
Stable isotope tracing
Cell culture and medium formulation for dissociated neuronal cultures. 
[U-13C6]glucose (CLM-1396), [U-13C6]leucine (CLM-2262), [U-13C5]
glutamine (CLM-1822), and [3-13C1]glucose (CLM-1393) were pur-
chased from Cambridge Isotope Laboratories. [U-13C4]β-hydroxy-
butyrate was purchased from Sigma-Aldrich (606030). When using 
a specific metabolic tracer, medium was formulated by replacing the 
substrate of interest with the isotopically labeled substrate while keep-
ing all other substrates present and unlabeled. As glycolytic provision 
of pyruvate can be rate limiting in primary neural preparations (Choi 
et al., 2009), it was present at a low concentration in rich Neuro-c, but 
tracing with [13C3]pyruvate was not conducted because results would 
largely mimic studies with labeled glucose. Tracing was conducted in 
six-well dishes, with each well considered a technical replicate for a 
given preparation of neurons. Immediately before adding rich incu-
bation medium for stable isotope tracing, maintenance medium was 
aspirated and cells were washed once with Neuro-c (Table 1) supple-
mented only with 26.19 mM sodium bicarbonate, 10.9 mM Hepes, and 
0.02 mM phenol red before adding 2 ml of rich incubation medium 
containing stable isotope tracers. Wells were washed and treated in-
dividually, working very quickly to minimize the time neurons were 
exposed to air, and offered stable isotope tracers after one wash.
Treatment with stable isotope tracers. Rich incubation medium 
for stable isotope tracing was Neuro-c supplemented with the follow-
ing: 26.19  mM sodium bicarbonate, 10.9  mM Hepes, 2  mM Gluta-
MAX, 100 U/ml penicillin, 100 µg/ml streptomycin, 8 mM glucose, 
0.8 mM leucine, 0.8 mM isoleucine, 0.8 mM valine, 2 mM β-hydroxy-
butyrate, 0.22  mM pyruvate, B27 supplement, and 0.02  mM phenol 
red. 20 mM NaCl was added for an osmolarity similar to Neurobasal 
medium (Thermo Fisher Scientific). When tracing with labeled gluta-
mine, GlutaMAX was omitted and replaced with 0.5 mM [U-13C5]glu-
tamine, β-hydroxybutyrate was omitted, and 10 µM MK801 was added 
to prevent excitotoxic injury.
Metabolite extraction and gas chromatography/mass spec-
trometry analysis. Cells were treated with rich incubation medium 
containing stable isotope tracers for 24 h. At the conclusion of the ex-
periment, 1 ml spent medium was set aside, spun to remove whole cells 
and debris, and kept at −80°C until analysis. The remaining medium 
was aspirated, and cells were washed with a 0.9% (wt/vol) NaCl solu-
tion. Polar metabolites and total fatty acids were extracted, derivatized, 
and analyzed as previously described (Vacanti et al., 2014). Ion frag-
ments composed of 13C atoms were quantified using gas chromatogra-
phy/mass spectrometry. Isotope enrichment was designated as M0 (no 
13C atoms), M1 (one 13C atom), M2 (two 13C atoms), etc. Molar percent 
enrichment (MPE) of isotopes was calculated as the percentage of all 
atoms within the metabolite pool that are labeled: 
  ∑ i=1 n  
 M i × i _____n , 
where n is the number of carbon atoms in the metabolite and Mi is 
the relative abundance of the i-th mass isotopomer. To determine the 
percentage of newly synthesized palmitate after tracer addition and 
the relative contribution of different substrates to lipogenic AcCoA, 
isotopomer spectral analysis was conducted using INCA software as 
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previously described (Metallo et al., 2011) and using the simplified net-
work outlined in Table 2.
Tracing with organotypic hippocampal cultures. For organotypic 
hippocampal cultures, slice culture medium was made as described in 
Animals and cell/tissue culture but supplemented with either [U-13C6]
glucose or [U-13C5]glutamine. As with tracing in dissociated cultures, 
all substrates were present during the experiments, and incorporation 
from either glucose or glutamine was measured by replacing unlabeled 
substrate with uniformly labeled substrate.
The powdered medium base is formulated with preexisting 
5.6 mM glucose and 2 mM glutamine that could not be removed, so 
only a fraction of the total pool of glucose or glutamine was labeled 
for this work (12.9 mM of 18.5 mM total glucose was labeled; 1 mM 
of 3  mM total glutamine was labeled). 48  h after tracer incubation, 
slices were thoroughly washed with 0.9% saline, removed from the 
insert, wrapped in aluminum foil, and immediately snap-frozen in 
liquid nitrogen. Tissue was disrupted with a Precellys Evolution sys-
tem (Bertin Technologies).
Glutamine uptake
Glutamine uptake, calculated as the difference in concentration in 
the extracellular medium after 24 h, was assessed using a 2950 Bio-
chemistry Analyzer (YSI).
Excitotoxicity
Glutamate excitotoxicity experiments were conducted in either a 
simple salts–based medium (Fig. S4, b–d) or customized Neuro-c 
(Fig. 6 c), and fluid changes and additions were made as quickly as pos-
sible to minimize exposure to air. For experiments conducted in salt-
based medium, maintenance medium (Neurobasal + B27, GlutaMAX, 
and penicillin/streptomycin) was replaced with 50 µl HBSS (137 mM 
NaCl, 5 mM KCl, 10 mM NaHCO3, 20 mM Hepes, 0.6 mM KH2PO4, 
1.4 mM CaCl2, 0.9 mM MgSO4, 10 mM glucose, and 1 mM pyruvate) 
with or without 100  µM glutamate and 10  µM glycine. Where indi-
cated, medium was supplemented with 2 mM β-hydroxybutyrate and 
2 mM leucine with or without 30 nM UK5099 (the HBSS medium for 
UK5099 treatment did not contain albumin). After a 30-min incubation 
at 37°C, 150 µl of maintenance medium was added, and cells were in-
cubated for 24 h before assessment of viability. Excitotoxic cell death 
was calculated as the difference in viability between groups with and 
without glutamate/glycine present in HBSS.
For experiments in customized Neuro-c, the medium composi-
tion matched the incubation medium used for stable isotope tracing. 
For measurements of excitotoxicity, maintenance medium was replaced 
with 100 µl supplemented Neuro-c medium with or without glutamate 
(500 µM). UK5099 (10 µM; medium contains B27 supplement with al-
bumin), MK801 (10 µM), or both were added 30 min before glutamate 
addition. Cells were incubated for 24 h before assessment of viability. 
Excitotoxic cell death (Fig.  6  c) was calculated as the difference in 
viability between groups with and without glutamate present in the me-
dium. For all excitotoxicity experiments, four biological replicates were 
conducted for each experiment with five technical replicates per plate.
Glutamate release and quantification
Glutamate release assays (Figs. 6 d and S4 f) were conducted in 96-
well plates. 24 h before the experiment, maintenance medium was re-
placed with 200 µl incubation medium with the same composition used 
for stable isotope tracing. Neurons were treated with or without 10 µM 
UK5099 for this period. Medium was then exchanged for fresh incu-
bation medium (groups containing 10 µM MK801 were pretreated for 
30 min) with or without 100 µM NMDA for 90 min. Medium was then 
harvested, spun to remove debris, and analyzed using a commercially 
available, Amplex red–based detection assay calibrated against gluta-
mate standards (A12221; Thermo Fisher Scientific). To determine the 
total releasable pool of cytoplasmic glutamate, cells in separate wells 
were permeabilized with the recombinant, mutant cytolysin PFO (3 
nM) to release cytoplasmic contents. Matched plates were used with an 
identical treatment scheme to determine effects of treatment on viabil-
ity using the LDH release assay.
For glutamate release assays to be analyzed by gas chromatog-
raphy/mass spectrometry (Fig. 6, a and b), six-well dishes of neuro-
nal cultures were treated similarly to other isotopic tracer experiments 
using [U-13C5]glutamine. After quickly washing cells with 0.9% NaCl, 
neurons were depolarized by treatment with 25  µM veratridine plus 
1  µM ouabain in artificial cerebrospinal fluid composed of 120  mM 
NaCl, 3.5 mM KCl, 1.3 mM CaCl2, 0.04 mM KH2PO4, 1 mM MgCl2, 
5 mM Hepes, and 8 mM glucose. After 90 min, the medium was col-
lected, centrifuged to remove any debris, and analyzed. Norvaline was 
used as an internal standard, and low phosphate was used to avoid po-
tential complications with MS analysis.
Quantification of intracellular glutamate (Fig. S2 c) was made 
using an Amplex Red–based detection assay calibrated against gluta-
mate standards (A12221; Thermo Fisher Scientific). After 24 h with or 
without UK5099 treatment, cells were scraped and pelleted after wash-
ing, disrupted by repeated freeze-thaw cycles in hypotonic PBS with 10 
nM recombinant, mutant PFO, and kept at −80°C until analysis.
Electrophysiology
At 13–18 DIV, half of the maintenance medium was replaced with new 
maintenance medium supplemented with 4 mM β-hydroxybutyrate and 
either 10 µM UK5099 or a DMSO vehicle control (final concentrations 
of 2 mM β-hydroxybutyrate and 5 µM UK5099). Cultures were treated 
for at least 24 h before coverslips were placed in a recording chamber 
perfused with external bath solution of artificial cerebrospinal fluid (pH 
7.3, 310–320 mOsm) composed of 167 mM NaCl, 2.4 mM KCl, 2 mM 
CaCl2, 1 mM MgCl2, 10 mM Hepes, 10 mM glucose, 1 mM pyruvate, 
2 mM β-hydroxybutyrate, 2 mM leucine, 100 µM picrotoxin (to inhibit 
GABAergic transmission), and 0.3  µM tetrodotoxin (to inhibit neu-
ronal action potentials).
To measure the size of the presynaptic readily releasable pool 
(Rosenmund and Stevens, 1996; Buren et al., 2016), 500 mM sucrose 
prepared in the external bath solution was applied for 4  s through a 
theta tube closely apposed to the recorded cell. Whole-cell patch-clamp 
recordings were conducted under voltage clamp at −70mV using an 
Axopatch 200B amplifier (Axon Instruments) and pClamp 10.2 soft-
ware (Molecular Devices). Cortical pyramidal neurons were selected 
by morphology for recording. Glass recording electrodes (3–6 MΩ) 
contained internal solution prepared with 145 mM K+-gluconate, 1 mM 
Table 2. Isotopomer spectral analysis
Contribution to lipogenic AcCoA (%) Description
AcM1.l (ab)→Ac (ab) AcCoA containing one 
13C 
tracer label
AcM2.l (ab)→Ac (ab) AcCoA containing two 
13C 
tracer labels
Ac.d (ab)→Ac (ab) Unlabeled AcCoA
8*Ac (ab)→Palm.s (abcdefghijklmnop)
De novo lipogenesis
 Palm.s→Palm Newly synthesized palmitate
 Palm.d→Palm Preexisting (unlabeled) palmitate
 0*Palm.s + 0*Palm.d→Palm.m Mixing of pools for measurement
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MgCl2, 10 mM Hepes, 1 mM EGTA, 2 mM Mg2+-ATP, and 0.5 mM 
Na+-GTP (pH 7.3, 280 mOsm). The access resistance (Ra) was typically 
10–20 MΩ, and recordings were rejected if Ra exceeded 25 MΩ. Traces 
were analyzed with Clampfit 10.2 (Molecular Devices).
Immunostaining of GluA2
To examine whether α-amino-3-hydroxy-5-methyl-4-isoxazolepropi-
onic acid receptor expression or distribution was altered by UK5099 
treatment, three to six coverslips from each preparation of neurons were 
fixed in 4% PFA and 4% sucrose for 15 min and washed with 0.03% 
Triton X-100 (Sigma-Aldrich) in PBS (PBST). Cells were then incu-
bated in methanol at −20°C for permeabilization, washed twice with 
PBST before blocking with 10% normal goat serum for 45 min at RT, 
and then incubated in primary antibodies overnight at 4°C (mouse anti- 
GluA2 [1:500; MAB397; EMD Millipore] and guinea pig anti-vGlut1 
[1:4,000, AB5905; EMD Millipore] in 2% normal goat serum PBST).
Cultures were washed three times with PBST before incuba-
tion with secondary antibodies at RT for 2 h (goat anti–mouse Alexa 
Fluor 568 [1:1,000, A11031; Invitrogen] and donkey anti–guinea pig 
AMCA [1:200, 706-155-148; Jackson ImmunoResearch Laboratories, 
Inc.]). Cells were then washed with PBST and mounted with Fluoro-
mount-G (0100-01; SouthernBiotech) on micro slides (2948-75X25; 
Corning). Images were taken under 63× oil lenses (1.4 NA) with an 
Axiovert 200 M epifluorescence microscope (ZEI SS) and ZEN 2012 
software. Dendrites were visualized with GluA2 staining, which stains 
both internal and surface GluA2 proteins. Seven to 15 images in the 
z-plane were acquired per cell, focusing on the dendritic tree, and the 
best-focused image planes were selected and exported as TIFF files. 
Two or three regions of interest on the dendritic tree in each image were 
selected in ImageJ 1.50a software and manually thresholded to remove 
background by adjusting the brightness and contrast for both GluA2 
and vGlut1 channels. Only GluA2 puncta colocalized with vGlut1 were 
selected for measurement of size and density using ImageJ.
Statistics
All statistical analysis was conducted with GraphPad Prism 5.0 using, 
where appropriate, either analysis of variance (repeated-measures with 
Dunnett’s post hoc test) or a paired, two-way Student’s t test. Where ap-
propriate, statistics were calculated on the square root of normalized data.
Online supplemental material
Fig. S1 shows that primary cortical neurons exhibit metabolic flexibil-
ity. Fig. S2 shows that inhibition of mitochondrial pyruvate uptake can 
adjust the abundance and composition of the neuronal glutamate pool 
while maintaining metabolic rates. Fig. S3 shows glutamine/glutamate 
oxidation is preferentially increased upon neuronal MPC inhibition. 
Fig. S4 shows that adjusting neuronal substrate metabolism can protect 
from glutamate excitotoxicity. Fig.S5 shows that UK5099 treatment 
does not compromise synaptic density.
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